Sundrug Co.,Ltd. (SDGCF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 13.63 means the share price is 13.63 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $3.30B is the value of all shares combined. Beta 0.06: the stock has moved about 94% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSundrug Co.,Ltd. (SDGCF) trades at $28.18. Sundrug Co., Ltd. operates drug and discount stores across Japan, offering a wide range of products from pharmaceuticals to fresh food. Market cap: $3.30B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SDGCF: SDGCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SDGCF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
SDGCF: 1/2 scored disciplines lean bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Sundrug Co.,Ltd. (SDGCF) Healthcare & Pipeline Overview
Sundrug Co., Ltd., a Japanese retailer, operates drug and discount stores offering pharmaceuticals, cosmetics, food, and household goods. With a market capitalization of $3.30B and a P/E ratio of 13.63, Sundrug distinguishes itself through a broad product portfolio and a widespread store network across Japan.
What Is the Investment Thesis for SDGCF?
Sundrug Co., Ltd. presents a stable investment profile, characterized by its established retail presence and diverse product offerings in the Japanese market. The company's P/E ratio of 13.63 suggests a reasonable valuation compared to its earnings, while a dividend yield of 3.26% offers an income component for investors. A low beta of 0.06 indicates that the stock is less volatile than the overall market. Growth catalysts include potential expansion of its store network and increased demand for healthcare and consumer products in Japan. However, investors may want to evaluate risks such as competition from other retailers and potential changes in consumer spending patterns. The company's profit margin of 3.7% and gross margin of 25.6% reflect its profitability and operational efficiency.
Based on FMP financials and quantitative analysis
SDGCF Key Highlights
Market capitalization of $3.30B, reflecting its significant presence in the Japanese retail market.
- P/E ratio of 13.63, indicating a potentially reasonable valuation compared to its earnings.
- Dividend yield of 3.26%, offering an income component for investors.
- Low beta of 0.06, suggesting lower volatility compared to the overall market.
- Gross margin of 25.6%, reflecting its ability to manage production costs and pricing strategies.
Who Are SDGCF's Competitors?
SDGCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ANSLF Ansell Limited | $21.64 | 0.00% | $3.05B | — |
| BUGDF Bumrungrad Hospital Public Company Limited | $4.75 | 0.00% | $3.78B | — |
| MAHLY MediPal Holdings Corporation | $18.30 | 0.00% | $3.75B | — |
| ATAI Atai Beckley Inc. | $7.35 | +0.82% | $2.72B | — |
| GEDSF Gedeon Richter PLC | $24.85 | 0.00% | $4.54B | 539-signal |
| DCHPF Dechra Pharmaceuticals PLC | $46.90 | -0.21% | $5.34B | — |
| DMRA Galecto, Inc. | $26.84 | +2.17% | $1.65B | 595-pillar |
| CGEM Cullinan Therapeutics, Inc. | $21.00 | -1.45% | $1.29B | 615-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are SDGCF's Key Strengths?
Established brand and reputation in the Japanese market.
- Diverse product offerings across drug stores and discount stores.
- Widespread store network providing convenient access for customers.
- Stable financial performance with consistent profitability.
What Are SDGCF's Weaknesses?
Relatively low profit margin compared to some competitors.
- Limited international presence.
- Dependence on the Japanese market.
- Potential vulnerability to changes in consumer spending patterns.
What Could Drive SDGCF Stock Higher?
Expansion of store network in Japan to increase market presence.
- Enhancement of e-commerce platform to cater to online shoppers.
- Potential development of new private label products to improve profitability.
- Strategic alliances and partnerships to expand product offerings and reach.
- Focus on healthcare services to cater to the aging population.
What Are the Key Risks for SDGCF?
Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Intense competition from other retailers in the Japanese market.
- Changes in government regulations affecting the healthcare and retail sectors.
- Economic downturns impacting consumer spending.
- Fluctuations in currency exchange rates affecting import costs.
- Limited financial disclosure due to OTC listing.
What Are the Growth Opportunities for SDGCF?
- Expansion of Store Network: Sundrug can expand its market presence by opening new stores in underserved regions of Japan. The Japanese retail market is characterized by regional disparities, with some areas having a higher concentration of retail outlets than others. By strategically locating new stores in these underserved regions, Sundrug can tap into new customer bases and increase its overall market share. This expansion strategy could target both urban and rural areas, adapting the store format and product offerings to suit the specific needs of each location. The timeline for this expansion could be phased over the next 3-5 years, with a target of opening 10-15 new stores per year.
- Enhancement of E-commerce Platform: Sundrug can enhance its e-commerce platform to cater to the growing demand for online shopping in Japan. The e-commerce market in Japan has been experiencing rapid growth, driven by increasing internet penetration and changing consumer behavior. By investing in its online platform, Sundrug can reach a wider customer base, offer greater convenience, and improve customer engagement. This enhancement could include features such as personalized recommendations, online ordering and delivery, and mobile app integration. The timeline for this enhancement could be implemented over the next 1-2 years, with a focus on improving user experience and expanding product offerings.
- Development of Private Label Products: Sundrug can develop and expand its range of private label products to improve profitability and differentiate itself from competitors. Private label products typically offer higher profit margins compared to branded products, allowing retailers to improve their overall profitability. By developing its own line of private label products, Sundrug can also create a unique brand identity and build customer loyalty. These products could include pharmaceuticals, health and beauty items, and household goods. The timeline for this development could be phased over the next 2-3 years, with a focus on quality, value, and customer satisfaction.
- Strategic Alliances and Partnerships: Sundrug can form strategic alliances and partnerships with other companies to expand its product offerings and reach new markets. These alliances could include partnerships with pharmaceutical companies, healthcare providers, and other retailers. By collaborating with other companies, Sundrug can leverage their expertise, resources, and distribution networks to enhance its competitive position and drive growth. For example, Sundrug could partner with a pharmaceutical company to develop and market new drugs, or with a healthcare provider to offer integrated healthcare services. The timeline for these alliances could be ongoing, with a focus on identifying mutually beneficial opportunities.
- Focus on Healthcare Services: Sundrug can expand its focus on healthcare services by offering a wider range of services in its drug stores and pharmacies. The demand for healthcare services in Japan is increasing, driven by an aging population and growing awareness of health and wellness. By offering services such as health checkups, medication counseling, and disease management programs, Sundrug can attract new customers and build stronger relationships with existing customers. This expansion could also include the integration of technology, such as telemedicine and remote monitoring, to improve access to healthcare services. The timeline for this expansion could be phased over the next 3-5 years, with a focus on providing high-quality, patient-centered care.
What Are SDGCF's Competitive Advantages?
- Established retail presence in Japan with a widespread store network.
- Diverse product offerings catering to a wide range of consumer needs.
- Strong brand recognition and customer loyalty.
- Efficient supply chain and distribution network.
What Does SDGCF Do?
Founded in 1957 and headquartered in Fuchu, Japan, Sundrug Co., Ltd. has evolved into a prominent operator of drug stores and discount stores throughout Japan. The company's business spans a diverse range of products, including pharmaceuticals, cosmetics, home appliances, clothing, car supplies, sports goods, alcoholic beverages, and fresh food. This extensive product offering allows Sundrug to cater to a wide customer base and meet various consumer needs. Sundrug's operations are divided into two primary segments: drug stores and discount stores. The drug stores focus on providing pharmaceutical products, health and beauty items, and over-the-counter medications, often including dispensing pharmacies. The discount stores offer a broader selection of products at competitive prices, attracting customers seeking value and convenience. With a workforce of 6662 employees, Sundrug maintains a significant retail presence across Japan. The company's strategy involves expanding its store network, enhancing its product offerings, and improving operational efficiency to drive growth and profitability. Sundrug's commitment to providing quality products and services has solidified its position in the Japanese retail market.
What Products and Services Does SDGCF Offer?
- Operates drug stores offering pharmaceuticals, health and beauty products, and over-the-counter medications.
- Manages dispensing pharmacies providing prescription medications and pharmaceutical services.
- Runs discount stores selling a wide range of products, including food, cosmetics, and household goods.
- Offers home appliances, clothing, car supplies, and sports goods in its discount stores.
- Sells alcoholic beverages and fresh food in select locations.
- Provides kerosene and other seasonal products.
How Does SDGCF Make Money?
- Generates revenue through the sale of pharmaceutical products and healthcare-related items in its drug stores.
- Earns income from the sale of a diverse range of products in its discount stores.
- Profits from dispensing prescription medications and providing pharmaceutical services in its pharmacies.
- Utilizes a retail network of drug and discount stores to reach customers across Japan.
What Industry Does SDGCF Operate In?
Sundrug Co., Ltd. operates within the competitive Japanese retail market, which includes drug stores, discount stores, and supermarkets. The healthcare and retail sectors in Japan are influenced by factors such as an aging population, increasing healthcare awareness, and evolving consumer preferences. The market is characterized by intense competition, with players like ANSLF, BUGDF, BUHPF, MAHLY, and MEPDF vying for market share. Sundrug differentiates itself through its diverse product offerings and widespread store network. The Japanese retail market is expected to grow steadily, driven by increasing consumer spending and demand for healthcare products and services.
Who Are SDGCF's Key Customers?
- Individuals seeking pharmaceutical products and healthcare-related items.
- Consumers looking for a wide range of products at competitive prices.
- Patients requiring prescription medications and pharmaceutical services.
- Households purchasing everyday essentials and household goods.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in JPY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 48 |
| 2026-08-26 | 48 |
| 2026-08-29 | 48 |
| 2026-09-01 | 48 |
| 2026-09-04 | 48 |
| 2026-09-07 | 48 |
| 2026-09-10 | 48 |
What changed?
The score has stayed at 48.
Over the same 18 days the stock moved +0.0%.
Earnings Track Record
Sundrug Co.,Ltd. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 17.3% above estimates on average.
Quarterly Financial Performance: Sundrug Co.,Ltd.
Revenue for Sundrug Co.,Ltd. came in at $1.40B during Q1 FY2027, a 3.5% improvement versus the preceding quarter. The company recorded net income of $52.2M, with diluted EPS of $0.45. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, SDGCF averaged $0.44 in diluted EPS.
SDGCF Valuation & Market Position
With a $3.30B market cap, Sundrug Co.,Ltd. sits in the mid-cap segment of the market.
Key Financial Metrics
Return on equity for Sundrug Co.,Ltd. stands at 11.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.8%, showing how much profit it generates from its asset base. SDGCF trades at a trailing price-to-earnings ratio of 13.63, below the Healthcare sector average of ~21.50x. A current ratio of 1.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Sundrug Co.,Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.94 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Sundrug Co.,Ltd. operates in the Pharmaceutical Retailers industry within the Healthcare sector. It is headquartered in Fuchu, Japan.
SDGCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Established brand and reputation in the Japanese market.
- Diverse product offerings across drug stores and discount stores.
- Widespread store network providing convenient access for customers.
- Stable financial performance with consistent profitability.
Bear Case
- Relatively low profit margin compared to some competitors.
- Limited international presence.
- Dependence on the Japanese market.
- Potential vulnerability to changes in consumer spending patterns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2027 | $1.40B | $52M | $0.45 |
| Q4 FY2026 | $1.35B | $47M | $0.41 |
| Q3 FY2026 | $1.42B | $58M | $0.50 |
| Q2 FY2026 | $1.39B | $48M | $0.41 |
Q1 FY2027 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from JPY at today's rate
SDGCF Latest News
-
Stocks That Hit 52-Week Highs On Wednesday
· Nov 27, 2019
SDGCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SDGCF.
Price Targets
Wall Street price target analysis for SDGCF.
SDGCF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SDGCF; grades run from A+ (80-100) to F (below 30).
Leadership: Hiroshi Sadakata
Unknown
Hiroshi Sadakata is the CEO of Sundrug Co., Ltd., leading a workforce of 6662 employees. As the CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. His leadership is crucial in navigating the competitive Japanese retail market and driving growth for Sundrug.
Track Record: Due to limited information, specific achievements, strategic decisions, and company milestones under Hiroshi Sadakata's leadership cannot be detailed. His tenure and impact on the company's performance require further research and data.
SDGCF OTC Market Information
The OTC Other tier, where Sundrug Co., Ltd. trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to meet minimum listing standards, such as asset size, revenue, or profitability. This lack of regulatory oversight and transparency increases the risk for investors.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in SDGCF.
- Lower liquidity can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the potential for fraud and manipulation.
- Price volatility can lead to significant losses for investors.
- OTC stocks are generally considered riskier than exchange-listed stocks.
- Verify the company's registration and regulatory filings.
- Review available financial statements and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Consider the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1957, indicating a long history.
- Sundrug has a significant number of employees (6662), suggesting a substantial operation.
- The company operates a network of drug stores and discount stores across Japan.
- Sundrug has a market capitalization of $3.30B, reflecting its size and value.
- The company has a P/E ratio of 13.63 and a dividend yield of 3.26%, suggesting some financial stability.
What Investors Ask About Sundrug Co.,Ltd. (SDGCF) — Healthcare
Is SDGCF a good stock?
Stock Expert AI does not rate SDGCF buy, sell or hold. Sundrug Co.,Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Sundrug Co.,Ltd. do?
Sundrug Co., Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offer a wide range of products, including food, cosmetics, home appliances, clothing, car supplies, sports goods, alcoholic beverages, and fresh food.
What are the key factors to evaluate for SDGCF?
Evaluate SDGCF on fundamentals, analyst consensus, and risk factors. P/E: 13.63x vs the S&P 500's ~20-25x. Sundrug Co., Ltd. presents a stable investment profile, characterized by its established retail presence and diverse product offerings in the Japanese market. Not financial advice.
How frequently does SDGCF data refresh on this page?
SDGCF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SDGCF's recent stock price performance?
Sundrug Co.,Ltd. (SDGCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand and reputation in the Japanese market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SDGCF overvalued or undervalued right now?
Sundrug Co.,Ltd. (SDGCF) trades at 13.63x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SDGCF?
Yes, most major brokerages offer fractional shares of Sundrug Co.,Ltd. (SDGCF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SDGCF's earnings and financial reports?
Sundrug Co.,Ltd. (SDGCF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SDGCF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC analysis based on general characteristics of the OTC market due to limited company-specific data.